title: Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
abstract: OBJECTIVE
  Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial. This study was to evaluate the efficacy and toxicity of LCAHFR combined with FP chemotherapy in treating esophageal cancer.
  
  
  METHODS
  Reports of randomized clinical trials on LCAHFR combined with FP chemotherapy for esophageal cancer published between January 1999 and January 2009 were researched through Wanfang, CNKI, and PubMed databases. RevMan4.2 software was used for Meta-analysis.
  
  
  RESULTS
  Twenty-one reports, including 2030 patients, were included in the meta-analysis. Of the 2030 patients, 1006 underwent LCAHFR (LCAHFR group), and 1024 underwent LCAHFR combined with FP chemotherapy (combination group). Compared with those of the LCAHFR group, the 1-, 2-, 3-, 5-years survival rates and 1-, 2-, 3-year local control rates of the combination group were significant increased, and the acute toxicity was also increased, but chronic toxicity showed no significant difference.
  
  
  CONCLUSIONS
  LCAHFR combined with FP chemotherapy can improve the survival rate and the local control rate of the patients with esophageal cancer. The increased acute toxicity need to be concerned, whereas the chronic toxicity needs a long-term observation.
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, PR China.
authors.forename: Chao-Xing
authors.initials: CX
authors.lastname: Liu
authors.forename: Xue-Ying
authors.initials: XY
authors.lastname: Li
authors.forename: Xian-Shu
authors.initials: XS
authors.lastname: Gao
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001991:Bronchitis / Q000209:etiology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D004940:Esophageal Stenosis / Q000209:etiology; D004941:Esophagitis / Q000209:etiology; D006801:Humans; D007970:Leukopenia / Q000209:etiology; D009325:Nausea / Q000209:etiology; D011658:Pulmonary Fibrosis / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D005641:Tegafur / Q000627:therapeutic use; D014498:Uracil / Q000627:therapeutic use
chemical_list: D005641:Tegafur; D014498:Uracil; D002945:Cisplatin